Hims
Hims is a telehealth company that provides personalized, 100% online treatment for men's health concerns, including hair loss, erectile dysfunction, weight loss, and mental health.
Classification
Profile
Funding
Funding details not yet available.
Fundraising & market
Accessible, modern telehealth for men's health issues like hair loss, ED, and mental health, delivered 100% online with personalized treatment plans.
Male consumers seeking discreet, convenient healthcare for hair loss, erectile dysfunction, weight loss, and mental health conditions.
Direct-to-consumer subscription and transactional sales for online consultations, prescription medications, and lab testing services.
Direct-to-consumer digital platform; online portal for self-service access to medical professionals and treatment plans.
Licensed medical professionals providing expert-backed care and personalized treatment plans for various health conditions.
Clinical operations, platform development, compliance, and customer acquisition for a fully online healthcare service.
Online telehealth platform, network of licensed medical professionals, and proprietary treatment protocols for men's health.
Connecting consumers with doctors, managing online consultations, prescribing treatments, and delivering personalized care plans.
Self-serve digital model offering accessible, personal healthcare grounded in clinical excellence for everyday life.
Competes in the telehealth space by focusing specifically on men's health with a modern, accessible approach to sensitive conditions.
Lack of accessible, discreet, and personalized healthcare options for men's health issues like hair loss, ED, and mental health.
- Launch a “clinical-outcome guarantee” - Reduce perceived risk, increase conversion, and differentiate from competitors
- The financial figures (≈ $1.5 B revenue, 95 % recurring) are sourced from the company’s 2024 SEC filing and investor deck, providing high‑confidence data[3].
- Subscriber retention metrics (82 % at 3 months, 85 % after 2 years) come from the company’s Q4 2024 earnings call, a primary source for operational performance[1].
Team details not yet available.
No investors recorded yet.